Fibroblast growth factors myocardial angiogenesis

Udelson JE, Dilsizian V Laham RJ, et al, Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000 102 1605-1610. 

M. Shou, V. Thirumurti, S. Rajanayagam, D.F. Lazarous, E. Hodge, J.A. Stiber, M. Pettiford, E. Elliott, S.M. Shah, and E.F. Unger, Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels, J Am Coll Cardiol 29, 1102-1106 (1997). 

Adenovirus-based Gene Therapy Therapeutic Angiogenesis with Adenovirus 5 Fibroblast Growth Factor-4 (Ad5FGF-4) in Patients with Chronic Myocardial Ischemia... 

Fibroblast growth factor protein has been infused into the coronary arteries, or injected directly into the heart muscle. Because of poor FGF protein pharmacokinetics (i.e., low retention by the heart) [18], stimulation of myocardial angiogenesis requires high doses of FGF protein intracoronary infusion over a long period of time. 

Sellke, F. W., Li, J., Stamler, A., Lopez, J. J., Thomas, K. A., and Simons, M. (19%). Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 120,182-188. 

Udelson, J. E., Dilsizian, V., Laham, R. J., Chronos, N., Vansant, J., Blais, M., Galt, J. R., Pike, M., Yoshizawa, G., and Simons, M. 2000. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation, 102,1605-10. 

---